glp-1 weight loss results GLP-1 Injections in Phoenix, Tempe,

The long-acting GLP-1 agonists segment held the largest market share of 63% in 2025, driven by the offering of once-weekly dosing, which drastically enhances patient adherence over daily therapies

Additionally, the use of PSM mitigates additional selection bias, ensuring the comparability of both cohorts

The primary endpoint was the percentage of people with at least one GI adverse event during the initiation and titration observation period, stratified by whether they were also taking metformin

The risk is elevated compared to those not on the medication, but it's not a guarantee

Microdosed GLP-1 helps rebalance appetite and metabolism for steady, natural weight loss without harsh side effects

US health care providers wrote more than nine million prescriptions for Wegovy and other injectable drugs used for weight loss during the last three months of 2022 alone